Chronic obstructive pulmonary disease burden attributable to tobacco and the trend change from 1990 to 2021 in China

被引:0
作者
Zhang, Zhenhong [1 ]
Wang, Kai [2 ]
Xu, Guoxiang [2 ,3 ]
Zhang, Rumin [2 ]
机构
[1] Shandong Second Med Univ, Sch Clin Med, Weifang, Peoples R China
[2] Zibo Cent Hosp, Dept Crit Care Med, Zibo 255020, Peoples R China
[3] Binzhou Med Univ, Sch Clin Med, Binzhou, Peoples R China
来源
TOBACCO INDUCED DISEASES | 2025年 / 23卷
关键词
China; chronic obstructive; pulmonary disease; Global; Burden of Disease; SMOKING-CESSATION; MORTALITY; RISK; COPD;
D O I
10.18332/tid/200196
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
INTRODUCTION Chronic obstructive pulmonary disease (COPD) poses a serious disease burden in China, and tobacco control is considered an effective and feasible means to reduce this burden. This study analyzes the impact of tobacco on the burden of COPD in China from 1990 to 2021. METHODS This study conducted a comprehensive secondary dataset analysis of COPD attributable to tobacco in China using data from the Global Burden of Disease (GBD) database. This covers a range of statistics, including number of deaths, mortality rates, disability-adjusted life years (DALYs), and DALY rates. Using Joinpoint regression analysis methods, we calculated the annual percentage change (APC) and average annual percentage change (AAPC) to assess trends in COPD attributable to tobacco for various age groups and gender in China. RESULTS In 2021, the age-standardized mortality rate (ASMR) of COPD attributable to tobacco in China was 35.46 per 100000, and the age-standardized DALY rate (ASDR) was 589.75 per 100000, both of which were higher than global levels. In China, the ASMR attributable to tobacco showed a consistent decline from 1990 to 2021 (AAPC=-3.69%, p<0.001), as did the ASDR (AAPC=-3.73%, p<0.001), consistent with trends observed globally and across five SDI regions, with China experiencing the fastest decline. In both 1990 and 2021, the burden of COPD attributable to tobacco was greater in males compared to females. During the years from 1990 to 2021, the ASMR of COPD attributable to tobacco and the ASDR showed a declining trend in males (AAPC=-3.29% and-3.41%, respectively) and in females (AAPC=-4.99% and-4.62%, respectively) (all p<0.001). The impact of COPD linked to tobacco use in China increased with age from 1990 to 2021, with the highest mortality and DALY rates observed in the population aged >= 70 years. Regarding secondhand smoke exposure, ASMR for females was 6.29 per 100000 and the ASDR was 119.03 per 100000, while the corresponding values for males were 7.80 per 100000 and 113.10 per 100000 , indicating a higher burden among females. CONCLUSIONS From 1990 to 2021, the age-standardized mortality rate and age- standardized DALY rate of COPD attributable to tobacco in China showed a declining trend; however, there remains a slight gap compared to global levels. Significant differences in smoking exposure were observed based on gender and age, with a heavier burden among males and the elderly.
引用
收藏
页数:10
相关论文
共 34 条
  • [1] Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
    Agusti, Alvar
    Celli, Bartolome R.
    Criner, Gerard J.
    Halpin, David
    Anzueto, Antonio
    Barnes, Peter
    Bourbeau, Jean
    Han, MeiLan K.
    Martinez, Fernando J.
    de Oca, Maria Montes
    Mortimer, Kevin
    Papi, Alberto
    Pavord, Ian
    Roche, Nicolas
    Salvi, Sundeep
    Sin, Don D.
    Singh, Dave
    Stockley, Robert
    Varela, M. Victorina Lopez
    Wedzicha, Jadwiga A.
    Vogelmeier, Claus F.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (04)
  • [2] The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease Exacerbations
    Au, David H.
    Bryson, Christopher L.
    Chien, Jason W.
    Sun, Haili
    Udris, Edmunds M.
    Evans, Laura E.
    Bradley, Katharine A.
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2009, 24 (04) : 457 - 463
  • [3] Lung Cancer 2020 Epidemiology, Etiology, and Prevention
    Bade, Brett C.
    Dela Cruz, Charles S.
    [J]. CLINICS IN CHEST MEDICINE, 2020, 41 (01) : 1 - +
  • [4] Spatial distribution, regional differences, and dynamic evolution of the medical and health services supply in China
    Chen, Baoqi
    Jin, Fulei
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [5] Effect of smoking on the development of chronic obstructive pulmonary disease in young individuals: a nationwide cohort study
    Chung, Chiwook
    Lee, Kyu Na
    Han, Kyungdo
    Shin, Dong Wook
    Lee, Sei Won
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [6] A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks
    Fang, Evandro F.
    Xie, Chenglong
    Schenkel, Joseph A.
    Wu, Chenkai
    Long, Qian
    Cui, Honghua
    Aman, Yahyah
    Frank, Johannes
    Liao, Jing
    Zou, Huachun
    Wang, Ninie Y.
    Wu, Jing
    Liu, Xiaoting
    Li, Tao
    Fang, Yuan
    Niu, Zhangming
    Yang, Guang
    Hong, Jiangshui
    Wang, Qian
    Chen, Guobing
    Li, Jun
    Chen, Hou-Zao
    Kang, Lin
    Su, Huanxing
    Gilmour, Brian C.
    Zhu, Xinqiang
    Jiang, Hong
    He, Na
    Tao, Jun
    Leng, Sean Xiao
    Tong, Tanjun
    Woo, Jean
    [J]. AGEING RESEARCH REVIEWS, 2020, 64
  • [7] A research agenda for aging in China in the 21st century
    Fang, Evandro Fei
    Scheibye-Knudsen, Morten
    Jahn, Heiko J.
    Li, Juan
    Ling, Li
    Guo, Hongwei
    Zhu, Xinqiang
    Preedy, Victor
    Lu, Huiming
    Bohr, Vilhelm A.
    Chan, Wai Yee
    Liu, Yuanli
    Ng, Tzi Bun
    [J]. AGEING RESEARCH REVIEWS, 2015, 24 : 197 - 205
  • [8] Health impact assessment to predict the impact of tobacco price increases on COPD burden in Italy, England and Sweden
    Fuertes, Elaine
    Marcon, Alessandro
    Potts, Laura
    Pesce, Giancarlo
    Lhachimi, Stefan K.
    Jani, Virjal
    Calciano, Lucia
    Adamson, Alex
    Quint, Jennifer K.
    Jarvis, Debbie
    Janson, Christer
    Accordini, Simone
    Minelli, Cosetta
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [9] GBD 2021 Diseases and Injuries Collaborators, 2024, LANCET, V403, P2133, DOI [10.1016/S0140-6736(24, DOI 10.1016/S0140-6736(24, DOI 10.1016/S0140-6736(24)00757-8]
  • [10] GBD 2021 Risk Factors Collaborators, 2024, Lancet, V403, P2162, DOI [DOI 10.1016/S0140-6736(24)00933-4, 10.1016/S0140-6736(24)00933-4]